IPO Plus

₹1,758.4

▲ +41.88 +2.44%

As of 06 Nov 2026 · delayed

NSE Listed · Pharmaceuticals

Evonile Pharma Limited (EVONILE)

Volume: 3,743Avg Vol 1W: 3,186Avg Vol 1M: 3,02452W Range:₹1,600.1₹1,785
NSE BSE www.novartis.in AI Report
Key Ratios
Checked just now
Market Cap₹4,342 Cr
Current Price₹1,758.4
Previous Close₹1,716.52
High / Low (52w)₹1,785 / ₹1,600.1
Volume3,743
Avg Vol (1W)3,186
Avg Vol (1M)3,024
Stock P/E67.55
Book Value₹312.56
Dividend Yield1.42%
ROE8.33%
ROA-17.52%
Revenue (TTM)—
Revenue Growth—
Profit Margin-118.64%
Total Debt—
Shares Outstanding2 Cr
Face Value₹5
EPS (TTM)₹26.03
P/B5.63
Debt / Equity0.01
50 DMA₹1,873.25
200 DMA₹1,363.79
Day change+2.44%
Price Chart
₹1,758.4▲ 109.20% · 1Y
₹2425₹75910.3L
2025-11-06
2026-11-06

20-day avg volume: 3K shares

Pros
  • Company is almost debt-free.
Cons
  • Stock trades at a high P/E of 68.
Quarterly Results
MetricDec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026Sept 2026
Revenue₹93 Cr₹84 Cr₹88 Cr₹90 Cr₹86 Cr₹91 Cr₹104 Cr₹56 Cr
EBITDA₹36 Cr₹34 Cr₹37 Cr₹33 Cr₹31 Cr₹30 Cr₹43 Cr₹-28 Cr
Net Profit₹25 Cr₹29 Cr₹28 Cr₹24 Cr₹16 Cr₹25 Cr₹32 Cr₹-78 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue₹569 Cr₹474 Cr₹414 Cr₹433 Cr₹437 Cr₹397 Cr₹398 Cr₹393 Cr
EBITDA₹87 Cr₹35 Cr₹48 Cr₹51 Cr₹117 Cr₹124 Cr₹131 Cr₹131 Cr
Net Profit₹52 Cr₹10 Cr₹21 Cr₹-4 Cr₹103 Cr₹85 Cr₹101 Cr₹93 Cr
EPS20.974.088.46-1.5141.8634.540.8737.74
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹982 Cr₹1,078 Cr₹1,002 Cr₹958 Cr₹983 Cr₹925 Cr₹948 Cr₹978 Cr
Total Liabilities₹223 Cr₹357 Cr₹291 Cr₹266 Cr₹207 Cr₹180 Cr₹163 Cr₹160 Cr
Equity₹759 Cr₹721 Cr₹711 Cr₹692 Cr₹776 Cr₹745 Cr₹785 Cr₹818 Cr
Total Debt————————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹-34 Cr₹57 Cr₹42 Cr₹75 Cr₹91 Cr₹82 Cr
Investing₹95 Cr₹87 Cr₹-153 Cr₹33 Cr₹-3 Cr₹18 Cr
Financing₹-37 Cr₹-36 Cr₹-30 Cr₹-121 Cr₹-64 Cr₹-64 Cr
Free Cash Flow₹-34 Cr₹57 Cr₹42 Cr₹75 Cr₹91 Cr₹82 Cr
Shareholding
Promoter 70.68% Institutions 2.72% Public 26.6%
Efficiency & Working Capital
ROCE4.9%
Interest Coverage103.9
Dividend Payout—
Debtor Days38 d
Inventory Days55 d
Payable Days56 d
Cash Conversion Cycle37 d
Working Capital Days93 d
Shareholding Details

As of 2026-09-30

Promoter70.7%
FII1.2%
DII1.5%
Institutions2.7%
Public26.6%
Promoter Pledge0%
No. of Shareholders38,127
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodMar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026Jul 2026Sept 2026
Promoters70.7%70.7%70.7%70.7%70.7%70.7%70.7%70.7%70.7%70.7%70.7%70.7%
FIIs0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%1.2%
DIIs0.5%0.5%0.5%0.5%0.5%0.5%0.5%0.6%0.5%1.4%1.4%1.5%
Public28.6%28.6%28.6%28.6%28.6%28.6%28.6%28.5%28.6%27.8%27.8%26.6%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders41,23939,26539,59638,92639,13339,04039,35339,46838,11636,50236,70638,127
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Waverise Investments LimitedShareholding of Promoter and Promoter Group56.5%1.39 Cr
Chryscapital Fund XShareholding of Promoter and Promoter Group10.3%25,47,189
Two Infinity PartnersShareholding of Promoter and Promoter Group3.9%9,65,149
Atul LimitedPublic Shareholding1.5%3,74,627
Board of Directors
NameDesignationYear
C SnookChairman (Non-Executive)2025
Sandra MartryesIndependent Director2025
SANKER PARAMESWARANIndependent Director2025
Shilpa JoshiWhole Time Director & Chief Financial Officer2025
Chandni MaruCompany Sec. & Compli. Officer2025
Gira SardesaiIndependent Director2025
Falin MajmudarWhole Time Director2025
Segments — Product
SegmentRevenueShare
Pharmaceuticals₹653 Cr80.8%
Generics₹39 Cr4.8%
OTC₹39 Cr4.8%
Animal Health₹77 Cr9.6%
Segments — Geography
RegionRevenueShare
India₹648 Cr98.8%
Other Countries₹8 Cr1.2%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹5321212
Corporate Actions
TypeDateValueRemark
forthcoming2026-07-23Board Meetings—
dividend2025-07-23₹25 (500%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025910014144
2025100001
2025100001
Insider / Designated-Person Trades

1 recent disclosure(s)

NOVARTIS AGDisposal · 1,74,50,680
Substantial Acquisitions (SAST)

2 disclosure(s)

Off Market29/07/2026 · 1,74,50,680
Off Market29/07/2026 · 1,74,50,680
Company Information
Incorporated1947
ChairmanC Snook
AuditorB S R & Co LLP
Investor Email[email protected]
🌐 www.novartis.in ↗

📍 The Inspire BKC Part 601 & 701, Bandra Kurla Complex Bandra(E), Mumbai, Maharashtra, 400051

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Euro Pratik Sales LimitedEurotex Industries and Exports Ltd.Eurotex Industries & ExportsEventions LimitedEveready Industries India Ltd.Everest Industries Ltd.Excel Industries Ltd.Excellent Wires and Packaging Ltd.Excelsoft Technologies LimitedExicom Tele Systems Ltd.Exide Industries Ltd.Exim Routes LimitedAll “E” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search

Telegram App